Penicillin: Difference between revisions
From IDWiki
No edit summary |
(added dosing) |
||
(4 intermediate revisions by the same user not shown) | |||
Line 1: | Line 1: | ||
− | == |
+ | ==Background== |
− | === |
+ | ===Nomenclature=== |
+ | *Broadly speaking, formulations of penicillin G are soluble and used for IV or IM administration, and penicillin V is used for oral administration but does not achieve high levels in the serum |
||
− | * Directly inhibits [[Penicillin-binding protein|penicillin-binding proteins]] |
||
+ | {| class="wikitable" |
||
− | [[Category:Beta-lactams]] |
||
+ | !Formulation |
||
+ | !Other Names |
||
+ | !Comments |
||
+ | |- |
||
+ | |sodium penicillin G |
||
+ | |sodium benzylpenicillin |
||
+ | crystalline penicillin |
||
+ | |soluble, used for IV |
||
+ | |- |
||
+ | |procaine penicillin G |
||
+ | |procaine benzylpenicillin |
||
+ | procaine penicilli |
||
+ | |less soluble, used for IM |
||
+ | |- |
||
+ | |benzathine penicillin G |
||
+ | |DBED penicillin |
||
+ | |less soluble than procaine, used for IM |
||
+ | |- |
||
+ | |penicillin V |
||
+ | |phenoxymethylpenicillin |
||
+ | |used for PO, but poor absorption |
||
+ | |} |
||
+ | |||
+ | ===Mechanism of Action=== |
||
+ | |||
+ | *Directly inhibits [[Penicillin-binding protein|penicillin-binding proteins]] |
||
+ | |||
+ | ===Spectrum of Activity=== |
||
+ | |||
+ | *Generally active against Gram-positive cocci, especially [[streptococci]] but some strains of [[Staphylococcus aureus]], most [[clostridia]], [[Neisseria]], and some [[Haemophilus influenzae]] |
||
+ | *Not active against aerobic Gram-negative bacilli |
||
+ | *Penicillin G is generally more active than penicillin V across all bacteria |
||
+ | |||
+ | ===Clinical Breakpoints=== |
||
+ | {| class="wikitable" |
||
+ | ! rowspan="2" |Species |
||
+ | ! colspan="3" |Breakpoints (μg/mL) |
||
+ | ! colspan="3" |Breakpoints (mm) |
||
+ | |- |
||
+ | !S |
||
+ | !I |
||
+ | !R |
||
+ | !S |
||
+ | !I |
||
+ | !R |
||
+ | |- |
||
+ | |[[Anaerobes]] except [[Bacteroides]] |
||
+ | |≤0.5 |
||
+ | |1 |
||
+ | |≥2 |
||
+ | | |
||
+ | | |
||
+ | | |
||
+ | |- |
||
+ | |[[Enterococcus]] |
||
+ | |≤8 |
||
+ | | |
||
+ | |≥16 |
||
+ | |≥15 |
||
+ | | |
||
+ | |≤14 |
||
+ | |- |
||
+ | |[[Neisseria gonorrhoeae]] |
||
+ | |≤0.06 |
||
+ | |0.12-1 |
||
+ | |≥2 |
||
+ | |≥47 |
||
+ | |27-46 |
||
+ | |≤26 |
||
+ | |- |
||
+ | |[[Neisseria meningitidis]] |
||
+ | |≤0.06 |
||
+ | |0.12-0.25 |
||
+ | |≥0.5 |
||
+ | | |
||
+ | | |
||
+ | | |
||
+ | |- |
||
+ | |[[Staphylococcus]] |
||
+ | |≤0.12 |
||
+ | | |
||
+ | |≥0.25 |
||
+ | |≥29 |
||
+ | | |
||
+ | |≤28 |
||
+ | |- |
||
+ | |[[Streptococcus pneumoniae]] |
||
+ | | |
||
+ | | |
||
+ | | |
||
+ | |≥20 |
||
+ | | |
||
+ | | |
||
+ | |- |
||
+ | |[[Streptococcus pneumoniae]] IV (nonmeningitis) |
||
+ | |≤2 |
||
+ | |4 |
||
+ | |≥8 |
||
+ | | |
||
+ | | |
||
+ | | |
||
+ | |- |
||
+ | |[[Streptococcus pneumoniae]] IV (meningitis) |
||
+ | |≤0.06 |
||
+ | | |
||
+ | |≥0.12 |
||
+ | | |
||
+ | | |
||
+ | | |
||
+ | |- |
||
+ | |[[Streptococcus pneumoniae]] PO (pen V) |
||
+ | |≤0.06 |
||
+ | |0.12-1 |
||
+ | |≥2 |
||
+ | | |
||
+ | | |
||
+ | | |
||
+ | |- |
||
+ | |[[Streptococcus]] (β-hemolytic) |
||
+ | |≤0.12 |
||
+ | | |
||
+ | | |
||
+ | |≥24 |
||
+ | | |
||
+ | | |
||
+ | |- |
||
+ | |[[Streptococcus]] (viridans group) |
||
+ | |≤0.12 |
||
+ | |0.25-2 |
||
+ | |≥4 |
||
+ | | |
||
+ | | |
||
+ | | |
||
+ | |} |
||
+ | |||
+ | == Dosing == |
||
+ | |||
+ | * Benzylpenicillin (penicillin G) |
||
+ | ** Standard dosing: 3 million units (1.8 g) IV q4h, or 4 million units (2.4 g) IV q6h |
||
+ | ** High dose (for critical illness, IE, and CNS penetration): 4 million units (2.4 g ) IV q4h |
||
+ | |||
+ | === Renal Dosing === |
||
+ | |||
+ | ==== Benzylpenicillin (Penicillin G) ==== |
||
+ | {| class="wikitable" |
||
+ | !GFR (mL/min) |
||
+ | !Standard Dose |
||
+ | !High Dose |
||
+ | |- |
||
+ | |>50 |
||
+ | |3 MU (1.8 g) IV q4h, or 4 MU (2.4 g) IV q6h |
||
+ | |4 MU (2.4 g ) IV q4h |
||
+ | |- |
||
+ | |10-50 |
||
+ | |3 MU (1.8 g) IV q6h |
||
+ | |3 MU (1.8 g) IV q4h |
||
+ | |- |
||
+ | |<10 |
||
+ | |3 MU (1.8 g) IV load, then 2 MU (1.2 g) IV q8h |
||
+ | |4 MU (2.4 g) IV load, then 2 MU (1.2 g ) IV q6h |
||
+ | |- |
||
+ | |CRRT |
||
+ | |2 MU (1.2 g) IV q6h |
||
+ | |3 MU (1.8 g) IV q6h |
||
+ | |} |
||
+ | |||
+ | == Safety == |
||
+ | |||
+ | === Adverse Reactions === |
||
+ | |||
+ | ==== Hypersensitivity Reactions ==== |
||
+ | |||
+ | * Can cause any type of [[hypersensitivity reaction]] (I to IV) |
||
+ | * Type I: [[anaphylaxis]] and [[urticaria]] |
||
+ | * Type II: [[autoimmune hemolytic anemia]] |
||
+ | * Type III: [[serum sickness-like reaction]] |
||
+ | * Type IV: |
||
+ | ** Delayed maculopapular drug rash |
||
+ | *** Usually after 7 to 10 days of starting and up to 1 to 3 days after stopping) |
||
+ | *** Progresses over days, with lesions that are relatively fixed |
||
+ | *** Can worsen over a few days after stopping, then resolves over 1 to 2 weeks |
||
+ | *** Pruritis is variable |
||
+ | *** Most commonly occur in the context of a viral infection |
||
+ | ** [[Contact dermatitis]] |
||
+ | [[Category:Β-lactams]] |
Latest revision as of 14:44, 30 August 2022
Background
Nomenclature
- Broadly speaking, formulations of penicillin G are soluble and used for IV or IM administration, and penicillin V is used for oral administration but does not achieve high levels in the serum
Formulation | Other Names | Comments |
---|---|---|
sodium penicillin G | sodium benzylpenicillin
crystalline penicillin |
soluble, used for IV |
procaine penicillin G | procaine benzylpenicillin
procaine penicilli |
less soluble, used for IM |
benzathine penicillin G | DBED penicillin | less soluble than procaine, used for IM |
penicillin V | phenoxymethylpenicillin | used for PO, but poor absorption |
Mechanism of Action
- Directly inhibits penicillin-binding proteins
Spectrum of Activity
- Generally active against Gram-positive cocci, especially streptococci but some strains of Staphylococcus aureus, most clostridia, Neisseria, and some Haemophilus influenzae
- Not active against aerobic Gram-negative bacilli
- Penicillin G is generally more active than penicillin V across all bacteria
Clinical Breakpoints
Species | Breakpoints (μg/mL) | Breakpoints (mm) | ||||
---|---|---|---|---|---|---|
S | I | R | S | I | R | |
Anaerobes except Bacteroides | ≤0.5 | 1 | ≥2 | |||
Enterococcus | ≤8 | ≥16 | ≥15 | ≤14 | ||
Neisseria gonorrhoeae | ≤0.06 | 0.12-1 | ≥2 | ≥47 | 27-46 | ≤26 |
Neisseria meningitidis | ≤0.06 | 0.12-0.25 | ≥0.5 | |||
Staphylococcus | ≤0.12 | ≥0.25 | ≥29 | ≤28 | ||
Streptococcus pneumoniae | ≥20 | |||||
Streptococcus pneumoniae IV (nonmeningitis) | ≤2 | 4 | ≥8 | |||
Streptococcus pneumoniae IV (meningitis) | ≤0.06 | ≥0.12 | ||||
Streptococcus pneumoniae PO (pen V) | ≤0.06 | 0.12-1 | ≥2 | |||
Streptococcus (β-hemolytic) | ≤0.12 | ≥24 | ||||
Streptococcus (viridans group) | ≤0.12 | 0.25-2 | ≥4 |
Dosing
- Benzylpenicillin (penicillin G)
- Standard dosing: 3 million units (1.8 g) IV q4h, or 4 million units (2.4 g) IV q6h
- High dose (for critical illness, IE, and CNS penetration): 4 million units (2.4 g ) IV q4h
Renal Dosing
Benzylpenicillin (Penicillin G)
GFR (mL/min) | Standard Dose | High Dose |
---|---|---|
>50 | 3 MU (1.8 g) IV q4h, or 4 MU (2.4 g) IV q6h | 4 MU (2.4 g ) IV q4h |
10-50 | 3 MU (1.8 g) IV q6h | 3 MU (1.8 g) IV q4h |
<10 | 3 MU (1.8 g) IV load, then 2 MU (1.2 g) IV q8h | 4 MU (2.4 g) IV load, then 2 MU (1.2 g ) IV q6h |
CRRT | 2 MU (1.2 g) IV q6h | 3 MU (1.8 g) IV q6h |
Safety
Adverse Reactions
Hypersensitivity Reactions
- Can cause any type of hypersensitivity reaction (I to IV)
- Type I: anaphylaxis and urticaria
- Type II: autoimmune hemolytic anemia
- Type III: serum sickness-like reaction
- Type IV:
- Delayed maculopapular drug rash
- Usually after 7 to 10 days of starting and up to 1 to 3 days after stopping)
- Progresses over days, with lesions that are relatively fixed
- Can worsen over a few days after stopping, then resolves over 1 to 2 weeks
- Pruritis is variable
- Most commonly occur in the context of a viral infection
- Contact dermatitis
- Delayed maculopapular drug rash